Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genetic Mutation”

3,294 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 3,294 results

Not applicableLooking for participantsNCT00359684
What this trial is testing

Use of Cysteamine in the Treatment of Cystinosis

Who this might be right for
Cystinosis
National Human Genome Research Institute (NHGRI) 330
Testing effectiveness (Phase 2)Looking for participantsNCT06383533
What this trial is testing

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Who this might be right for
Bile Duct Adenocarcinoma Non-ResectableHER2 Gene Mutation
Zhejiang Cancer Hospital 28
Early research (Phase 1)Ended earlyNCT04835714
What this trial is testing

Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 8
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Not applicableStudy completedNCT04425200
What this trial is testing

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

Who this might be right for
Prostatic Neoplasms
AstraZeneca 205
Post-approval studies (Phase 4)Study completedNCT02744664
What this trial is testing

Cryotherapy Combine Icotinib for Advanced NSCLC Treatment

Who this might be right for
Lung Neoplasms
Fuda Cancer Hospital, Guangzhou 60
Testing effectiveness (Phase 2)Study completedNCT00827684
What this trial is testing

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Who this might be right for
Metastatic Colorectal Cancer
Vejle Hospital 50
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Not applicableLooking for participantsNCT02432092
What this trial is testing

Pediatric Cardiomyopathy Mutation Analysis

Who this might be right for
CardiomyopathiesDilated CardiomyopathyHypertrophic Cardiomyopathy+3 more
Indiana University 300
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Early research (Phase 1)Study completedNCT03636204
What this trial is testing

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Who this might be right for
HealthyFrontotemporal Dementia
Alector Inc. 64
Testing effectiveness (Phase 2)Study completedNCT03812809
What this trial is testing

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Who this might be right for
NSCLC
Beta Pharma Shanghai 226
Not applicableNo Longer AvailableNCT04489433
What this trial is testing

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals
Early research (Phase 1)UnknownNCT05019534
What this trial is testing

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
West China Hospital 12
Not applicableUnknownNCT02738684
What this trial is testing

Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

Who this might be right for
Lung Adenocarcinoma
Southwest Hospital, China 100
Not applicableUnknownNCT05162508
What this trial is testing

Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease

Who this might be right for
SARS-CoV2 InfectionCOVID-19 Acute Respiratory Distress SyndromeMutation
Assistance Publique - Hôpitaux de Paris 2,000
Early research (Phase 1)Ended earlyNCT04916236
What this trial is testing

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Who this might be right for
Pancreatic CancerColorectal CancerNon-small Cell Lung Cancer+1 more
The Netherlands Cancer Institute 24
Not applicableActive Not RecruitingNCT04285398
What this trial is testing

Prospective Natural History Study of Retinitis Pigmentosa

Who this might be right for
Retinitis Pigmentosa
SparingVision 82
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05640726
What this trial is testing

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Who this might be right for
Rectal Cancer
Fujian Cancer Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06456138
What this trial is testing

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Who this might be right for
KRAS Mutation-Related TumorsAdvanced Lung CancerRefractory Tumor
Shanghai Chest Hospital 60
Load More Results